Audited Financial Results (Standalone and Consolidated) for the Quarter and Year ended 31.03.2026
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Parenterals reported strong audited results for FY2025-26. On standalone basis, revenue was Rs 1,242.69 million with PAT of Rs 167.77 million (vs Rs 102.83 million last year, growth of 63%). On consolidated basis, revenue surged to Rs 3,509.93 million (vs Rs 1,631 million last year), a growth of 115%, driven by the acquisition of Noumed Life Sciences Limited (UK) in which the company holds 74.64% controlling stake. Consolidated PAT was Rs 144.27 million (vs Rs 101.14 million). The company is preparing for an IPO and has filed its DRHP. Statutory auditors R Kabra & Co. LLP issued an unmodified opinion. The company expanded its cash position to Rs 4,169.66 million on consolidated basis from equity raises.
Strong revenue growth and PAT growth signal solid operational performance; however, the significant increase in borrowings and working capital pressure should be monitored. The IPO preparation and acquisition-driven growth could be positive catalysts for the stock.